NSE: TORNTPHARM · Healthcare · Pharmaceuticals · Market cap ₹1,80,292 Cr
· Prev close ₹4,773.00 · Volume 3.22 L · 52W ₹3,602–5,250
Day range for 9 Nov not in the price history yet · 8 Nov ₹4,750.10–4,800.00
Last 4 quarters: profit −0.7% on the 4 beforeShare price +3.4% in a month
If profit compounds at 29.2% (CAGR) and the stock ends at 25×, buying at ₹4,740 returns about 15.0% CAGR over 10 years.
| Growth assumption | Profit growth (CAGR) | Return, 10Y CAGR |
|---|---|---|
| Yours | 29.2% | 15.0% |
| Delivered FY22–26 | 29.2% | 15.0% |
| Net profit, last 4 quarters vs the 4 before | −0.7% | −11.7% |
| Half the delivered pace | 14.6% | 2.0% |
Delivered FY22–26 CAGR 29.2%
This is an exit-multiple calculation, not a discounted cash flow. Inputs: EPS for the 4 quarters Dec 2025 to Sep 2026 ₹59.20, price ₹4,740.10 (9 Nov 2026, 2:47 pm IST price). Formula: return = (EPS × exit P/E ÷ price)^(1/10) × (1 + growth) − 1. Net profit growth is applied to EPS, so the share count is held constant. A profit fall of 100% or more has no rate and is left blank. Dividends ignored. Arithmetic, not a forecast.